JW Pharmaceutical Launches Low-Dose Pitavastatin Combination Drug "Livarozet 1/10mg"

Low-Dose Option Added to Existing Livarozet Product Lineup

JW Pharmaceutical announced on June 1 that it has launched "Livarozet 1/10mg," a low-dose version of its dyslipidemia treatment, Livarozet.

Livarozet is Korea's first dual combination modified new drug for dyslipidemia, combining pitavastatin and ezetimibe. Pitavastatin works by suppressing cholesterol production in the liver, while ezetimibe inhibits cholesterol absorption in the small intestine. Both active ingredients help lower low-density lipoprotein cholesterol (LDL-C) levels through these respective mechanisms.

JW Pharmaceutical's dyslipidemia treatment 'Livalojet'. JW Pharmaceutical

The newly released Livarozet 1/10mg is a low-dose combination drug that contains 1mg of pitavastatin and 10mg of ezetimibe. With the addition of the 1/10mg dose to the existing Livarozet 2/10mg and 4/10mg products, healthcare providers now have a wider selection of dosage options, allowing for more tailored treatment based on the patient's LDL-C levels and therapeutic goals.

In particular, Livarozet 1/10mg can be offered as a treatment option in a variety of clinical scenarios, such as for patients who require low-dose statin therapy or those who need further LDL-C control after existing monotherapy.

JW Pharmaceutical is expanding its product lineup with pitavastatin original monotherapy "Livaro," as well as Livarozet, "Livaro High," and "Livaro Pheno," among others. Through this, the company aims to segment its pitavastatin-based lineup and strengthen the competitiveness of its original combination drugs.

A representative from JW Pharmaceutical stated, "The launch of Livarozet 1/10mg is significant in that it expands our product lineup, enabling healthcare professionals to select more specialized treatment strategies according to each patient's condition and treatment objectives. Moving forward, we will continue to provide a variety of treatment options focused on the Livaro family to support LDL-C management and cardiovascular disease prevention for patients with dyslipidemia."

Meanwhile, JW Pharmaceutical is also conducting disease awareness activities targeting patients. Through the "Dangbu, Statin" campaign, the company provides guidance on treatment goals, medication usage, and information regarding adverse reactions to help dyslipidemia patients better manage their condition and access information about statin therapy.

This content was produced with the assistance of AI translation services.